A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.

D A, Papanicolaou,; S N, Ather,; H, Zhu,; Y, Zhou,; J, Lutkiewicz,; B B, Scott,; J, Chandler,

doi:10.1007/s12603-013-0335-x

Public

A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.

Published in The journal of nutrition, health & aging • Jan 1, 2013

Authors:

Papanicolaou, D A

Ather, S N

Zhu, H

Abstract

BACKGROUND: Sarcopenia, the age-related loss of muscle mass [defined as appendicular LBM/Height2 (aLBM/ht2) below peak value by>1SD], strength and function, is a major contributing factor to frailty in the elderly. MK-0773 is a selective androgen receptor modulator designed to improve muscle functio...

Subject

Absorptiometry

Photon

Aged

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!